ACRIVON THERAPEUTICS INC ACRV
COMMON STOCK · Common Stock · CUSIP 004890109
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersWatertown, MA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 20.9m as of 2022-12-09, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $11.38.
Biggest buyers
| RA CAPITAL MANAGEMENT, L.P. | New | +4.8m |
| PERCEPTIVE ADVISORS LLC | New | +3.0m |
| Sands Capital Alternatives, LLC | New | +1.7m |
| CITADEL ADVISORS LLC | New | +1.6m |
| MARSHALL WACE, LLP | New | +1.2m |
| WELLINGTON MANAGEMENT GROUP LLP | New | +900.1k |
| NEA Management Company, LLC | New | +481.7k |
| HealthCor Management, L.P. | New | +284.2k |
| BANK OF MONTREAL /CAN/ | New | +42.4k |
| GOLDMAN SACHS GROUP INC | New | +38.8k |
Biggest sellers
| None |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| RA CAPITAL MANAGEMENT, L.P. 13D · may seek influence +7.2 pts · filed 2026-04-23 | 28.8% |
| Sands Capital Life Sciences Pulse Fund II, L.P. 13G · passive investor -1.5 pts · filed 2026-08-13 | 5.3% |
Fell to 5% or below in the last year: CITADEL ADVISORS LLC (0.0%, 2026-05-15)
Insider purchases and sales in Q4 2022
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q1 2021 | 0 | — | 0 | — | — |
| Q2 2021 | 0 | — | 0 | — | — |
| Q3 2021 | 0 | — | 0 | — | — |
| Q4 2021 | 0 | — | 0 | — | — |
| Q1 2022 | 0 | — | 0 | — | — |
| Q2 2022 | 0 | — | 0 | — | — |
| Q3 2022 | 0 | — | 0 | — | — |
| Q4 2022 | 1 | $42.4m | 0 | — | — |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2022-11-17 | RA Capital Healthcare Fund LP +4 Director · See Footnotes | Bought | $42.4m3.4m shares |
| 2022-11-17 | Chione Ltd +4 10% owner | Bought | $5.0m400.0k shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q4 2022
| Manager | Shares | Change |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. 1.12% of their portfolio | 4.8m $55.4m | New |
| PERCEPTIVE ADVISORS LLC 1.00% of their portfolio | 3.0m $34.7m | New |
| Sands Capital Alternatives, LLC 5.21% of their portfolio | 1.7m $19.0m | New |
| CITADEL ADVISORS LLC 0.02% of their portfolio | 1.6m $18.2m | New |
| MARSHALL WACE, LLP 0.04% of their portfolio | 1.2m $14.1m | New |
| WELLINGTON MANAGEMENT GROUP LLP 0.00% of their portfolio | 900.1k $10.0m | New |
| FEDERATED HERMES, INC. 0.03% of their portfolio | 823.3k $9.5m | Not comparable |
| NEA Management Company, LLC 0.25% of their portfolio | 481.7k $4.4m | New |
| HealthCor Management, L.P. 3.00% of their portfolio | 284.2k $3.3m | New |
| BANK OF MONTREAL /CAN/ 0.00% of their portfolio | 42.4k $545.0k | New |
| GOLDMAN SACHS GROUP INC 0.00% of their portfolio | 38.8k $447.0k | New |
| TWO SIGMA INVESTMENTS, LP 0.00% of their portfolio | 21.5k $248.1k | New |
| MILLENNIUM MANAGEMENT LLC 0.00% of their portfolio | 19.6k $226.0k | New |
| DAFNA Capital Management LLC 0.05% of their portfolio | 15.6k $180.3k | New |
| UBS Group AG 0.00% of their portfolio | 4.7k $54.7k | New |
| BARCLAYS PLC 0.00% of their portfolio | 4.1k $47.7k | First filing |
| MORGAN STANLEY 0.00% of their portfolio | 869 $10.0k | New |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 159 $2.0k | New |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | New |